LYON, France, Feb. 14, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that the Journal of Endourology published results in its February 2008 issue from a head-to-head study entitled “Transrectal High-Intensity Focused Ultrasound Devices: A Critical Appraisal of Available Evidence.” Based on a thorough review of the existing medical literature, the objective of the study was to evaluate clinical outcomes and unique characteristics comparing EDAP’s Ablatherm(r)-HIFU versus Sonablate500(r) for the treatment of prostate cancer.
